Component
Death or type 1 retinopathy of prematurity composite
Death or type 1 retinopathy of prematurity composite. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Death or type 1 ROP occurred in 29% with myo-inositol versus 21% with placebo (adjusted RR 1.41, 95% CI 1.08–1.83).
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/inositol-research/30357297.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "b3301c8c680b4b3c6424dfb6677ae55839221db1d3cd51d9df4724b9cf35d57f", "start_char": 0, "end_char": 2589, "text_sha256": "b3301c8c680b4b3c6424dfb6677ae55839221db1d3cd51d9df4724b9cf35d57f"}
- experimental_model
- Multicenter randomized neonatal trial stopped early
- exposure
- Myo-inositol 40 mg/kg every 12 hours, initially IV then enteral, for up to 10 weeks versus placebo
- limitations
- Early termination limits estimates but does not remove the mortality signal. Different era, gestational ages, treatment duration and endpoints may contribute to divergence from early trials; the explanation remains unresolved.
- nutrient_topic
- Inositol research collection; topical membership is not evidence of a direct dietary effect. · Inositol (stereoisomer family)
- organism
- Homo sapiens
- plain_language
- The later larger neonatal trial did not reproduce the expected overall benefit.
- primary_references
- [ino-p30357297] Effects of Myo-inositol on Type 1 Retinopathy of Prematurity Among Preterm Infants <28 Weeks' Gestational Age: A Randomized Clinical Trial. (2018). https://pubmed.ncbi.nlm.nih.gov/30357297/ DOI: 10.1001/jama.2018.14996
- tissue_or_cell_type
- 638 infants born before 28 weeks at 18 US centers
Inositol: synthesis, signaling, mineral interactions and conditional deficiency (2026-09-17) · lines 1445–1456
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Multicenter randomized neonatal trial stopped early · source_derived_draft · unverified_draft
### ino-preterm-2018-composite Death or type 1 ROP occurred in 29% with myo-inositol versus 21% with placebo (adjusted RR 1.41, 95% CI 1.08–1.83). Condition category: normal nutrient_topic: Inositol research collection; topical membership is not evidence of a direct dietary effect. plain_language: The later larger neonatal trial did not reproduce the expected overall benefit. organism: Homo sapiens tissue_or_cell_type: 638 infants born before 28 weeks at 18 US centers experimental_model: Multicenter randomized neonatal trial stopped early limitations: Early termination limits estimates but does not remove the mortality signal. Different era, gestational ages, treatment duration and endpoints may contribute to divergence from early trials; the explanation remains unresolved. exposure: Myo-inositol 40 mg/kg every 12 hours, initially IV then enteral, for up to 10 weeks versus placebo evidence_span: {"source_cache": "artifacts/inositol-research/30357297.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "b3301c8c680b4b3c6424dfb6677ae55839221db1d3cd51d9df4724b9cf35d57f", "start_char": 0, "end_char": 2589, "text_sha256": "b3301c8c680b4b3c6424dfb6677ae55839221db1d3cd51d9df4724b9cf35d57f"} [ino-p30357297] Effects of Myo-inositol on Type 1 Retinopathy of Prematurity Among Preterm Infants <28 Weeks' Gestational Age: A Randomized Clinical Trial. (2018). https://pubmed.ncbi.nlm.nih.gov/30357297/ DOI: 10.1001/jama.2018.14996
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.